For changes in insulin level, although the result was not statistically significant, the effect size showed that GLP-1 receptor agonists could increase insulin content in vivo, which is consistent with the pharmacological effects of the drug
The lawsuit alleges both drugmakers "knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis," and that their "failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate." Gastroparesis is a condition that slows or stops the movement of food from the stomach to the small intestine, according to the National Institute of Diabetes and Digestive and Kidney Diseases
Additionally, TMAO damages renal cells through the PI3K/Akt/NF-kappa B pathway
Keeping a record of doses and reactions helps us track progress and share accurate information with our provider
More energy or improved mood, and better rest
